Peptide Antibiotics Market Size, Share & Trends Analysis Report By Disease (Skin Infection, HABP/VABP), By Route of Administration (Injectable, Oral), By Product, By Distribution Channel, By Region,- Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2025-2034

Peptide Antibiotics Market Size and Research

The global peptide antibiotics market was valued at USD 5.35 billion in 2024 and is projected to reach USD 8.97 billion by 2034, registering a CAGR of 5.3% from 2025 to 2034. The global peptide antibiotics market growth is attributed to the increasing prevalence of hospital-acquired infections and bacterial skin infections.

Peptide Antibiotics Market Size 2024 To 2034

Peptide Antibiotics Market Key Takeaways

  • By region, North America dominated the peptide antibiotics market in 2024.
  • By region, Asia Pacific is expected to grow fastest during the forecast period.
  • By product insights, the non-ribosomal synthesized peptide antibiotics segment dominated the market growth in 2024.
  • By product insights, the ribosomal synthesized peptide antibiotics segment is expected to grow fastest during the forecast period.
  • By disease insights, the skin infection segment dominated the market growth in 2024.
  • By disease insights, the bloodstream infections segment is expected to grow the fastest during the forecast period.
  • By route of administration insights, the injectable segment dominated the peptide antibiotics market in 2024.
  • By route of administration insights, the oral segment is expected to grow fastest during the forecast period.
  • By distribution channel insights, the hospital pharmacies segment dominated the market share in 2024.
  • By distribution channel insights, the online pharmacies segment is expected to grow the fastest during the forecast period.

Peptide Antibiotics Market Overview

The peptide antibiotics market deals with a short chain of amino acids that has the potential to inhibit or kill the growth of microorganisms such as fungi, bacteria, and viruses by disrupting essential intracellular processes, interfering with cell wall synthesis, and disrupting their cell membranes. These peptides can be synthetically designed in a laboratory and found naturally in various organisms. The increasing prevalence of acute and chronic infectious diseases is expected to drive market growth.

The peptide antibiotics market is witnessing rapid growth due to factors such as rising technological advancements in peptide synthesis, increasing focus on targeted therapies and precision medicine, and increasing growth in new product launches and product approvals. In addition, the growing need for peptide antibiotics in clinics and hospitals and the rise in the cases of antibiotic resistance are further expected to drive the market growth.

Major Trends Contributing to Peptide Antibiotics Market Growth

  • Government initiatives: Both non-government bodies and government organizations are providing funding that enhances innovation in these fields, contributing to propelling market growth.
  • Increasing R&D: The increasing research and development spending on novel antibiotic peptides. Pharmaceutical and biotech companies are focusing on new classes of peptides that are expected to drive the growth of the peptide antibiotics market.
  • Improvements in bioengineering: The improvements in formulation techniques and formulation are increasing the bioavailability, efficacy and stability of peptide antibiotics and are further expected to enhance market growth during the forecast period.

Report Scope of Peptide Antibiotics Market

Report Coverage Details
Market Size in 2025 USD 5.63 Billion
Market Size by 2034 USD 8.97 Billion
Growth Rate From 2025 to 2034 CAGR of 5.3%
Base Year 2024
Forecast Period 2025-2034
Segments Covered Product, Disease, Route of Administration, Distribution Channels, Region
Market Analysis (Terms Used) Value (US$ Million/Billion) or (Volume/Units)
Regional scope North America; Europe; Asia Pacific; Latin America; MEA
Key Companies Profiled Pfizer Inc.; Teva Pharmaceuticals Industries Limited; AbbVie Inc.; Merck & Co., Inc.; The Menarini Group; Sanofi; Eli Lilly and Company; GSK plc.; NPS Pharmaceuticals; Xellia Pharmaceuticals.

Advancements in customized orthodontic treatments create market opportunity

The rising advancements in drug delivery technologies are presenting significant growth opportunities for the market of peptide antibiotics. Researchers are continuously exploring innovative formulations, such as peptide modifications, prodrug strategies, and delivery systems to improve bioavailability, stability, and targeted drug release. In addition, institutional research is substantially invested, with a growing pool of talented technocrats and scientists interested in the arena for innovative therapeutics containing antimicrobial peptides for rare diseases, which may create significant opportunities in the peptide antibiotics market in the coming years.

Limited Commercialization Success may Restrain Market Growth 

Leading to uncertainties regarding market success, not all antimicrobial peptides successfully transition from the laboratory to commercial products, despite promising research. In addition, regulatory challenges for the approval of antimicrobial peptides also pose challenges, leading to increased development costs and delays in market entry, which may further be expected to restrain the growth of the peptide antibiotics market.

Segment Insights 

Peptide Antibiotics Market By Product Insights

The non-ribosomal synthesized peptide antibiotics segment dominated the peptide antibiotics market in 2024. The segment growth in the market is attributed to the rising demand for novel therapeutic options, the increasing prevalence of antibiotic resistance, and the increasing unique potential to combat multidrug-resistant pathogens. In addition, the ribosomal synthesized peptide antibiotics segment is expected to grow fastest during the forecast period. The segment growth in the market is driven by rising advancements in genetic engineering and synthetic biology and increasing demand for novel therapeutic approaches to combat antimicrobial infections.

Peptide Antibiotics Market By Disease Insights

The skin infection segment dominated the peptide antibiotics market in 2024. The segment is witnessing rapid growth in growth due to the increasing incidence rate of cellulitis and the rising prevalence and incidence of skin infections across the globe. Whereas the bloodstream infections segment is expected to grow fastest during the forecast period. The segment growth in the market is contributed by the increasing ability to combat infections, increasing demand for novel antimicrobial solutions, and increasing public health challenges across the globe.

Peptide Antibiotics Market By Route of Administration Insights

The injectable segment dominated the peptide antibiotics market in 2024. The growing research in the field of peptides, the urgent need for innovative antimicrobial therapies, and rising incidences of multidrug-resistant infections are expected to drive the segment growth. Furthermore, the oral segment is expected to grow fastest during the forecast period. The segment growth in the market is attributed to the increasing demand for patient-friendly and convenient treatment options and rising advances in drug delivery technologies and peptide engineering.

Peptide Antibiotics Market By Distribution Channel Insights

The hospital pharmacies segment dominated the peptide antibiotics market in 2024. The segment plays an important role in the market driven by the critical need for effective antimicrobial therapies in inpatient care industries and the increasing prevalence of multidrug-resistant bacterial infections. Whereas the online pharmacies segment is anticipated to grow fastest during the forecast period. Online pharmacies are offering efficiency and accessibility for both healthcare providers and patients and emerging as a critical distribution channel in the market.

Pie Graph 0

Peptide Antibiotics Market By Regional Insights 

North America dominated the peptide antibiotics market in 2024. The market growth in the region is attributed to the rapid development of advanced peptide therapies, increased collaborations between research institutions and pharmaceutical companies, and rising strong emphasis on technological innovation. The U.S. and Canada are dominating countries driving the market growth.

Stacked Graph 0

Asia Pacific Peptide Antibiotics Market Trends

Asia Pacific is expected to grow fastest during the forecast period. The market in the region is witnessing rapid growth due to increased healthcare investments, growing demand for innovative therapeutic solutions, increasing growth in infectious diseases, and growing healthcare and government institutions to recognize the potential of antimicrobial peptides. China, India, Japan, and South Korea are the fastest growing countries in the market.

Some of The Prominent Players in The Peptide Antibiotics Market Include:

  • Merck & Co., Inc.
  • The Menarini Group
  • Sanofi
  • Eli Lilly and Company
  • GSK Plc.
  • NPS Pharmaceuticals
  • Xellia Pharmaceuticals

Peptide Antibiotics Market Recent Breakthroughs

  • In March 2025, The Dutch Research Council (NWO) launched funding for five projects as part of the KIC call ‘Antimicrobials for the preclinical pipeline’. This will allow them to accelerate the implementation of such alternatives and conduct research into new antimicrobial agents.
  • In January 2025, Bruker Corporation announced the launch of a quantum cascade laser (QCL) based infrared imaging microscope the LUMOS™ II ILIM. The new LUMOS II ILIM enables pharma and life science researchers to capture ultrafast IR images of expansive areas with enhanced spatial resolution and redefines performance standards.

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the Peptide Antibiotics Market

By Product

  • Ribosomal Synthesized Peptide Antibiotics
  • Non-ribosomal Synthesized Peptide Antibiotics

By Disease

Skin Infection

HABP/VABP

Blood Stream Infections

Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Regional

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa (MEA)

Proceed To Buy

USD 4500
USD 3900
USD 1900
USD 1200

Customization Offered

  • check-img Cross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers